What it is
Endothelin-1 is a peptide of 21 amino acids made by endothelial cells, the thin layer lining every blood vessel. Its job is to make vessels narrow. It was isolated and named in 1988 by Yanagisawa and colleagues, whose Nature paper described "an endothelium-derived 21-residue vasoconstrictor peptide" and called it "one of the most potent vasoconstrictors known" (PMID 2451132).
The chain is folded by two disulfide bridges — sulfur-to-sulfur bonds between cysteine residues. UniProt's record for the human precursor (P05305, read 2026-11-13) places them between the first and fifteenth residues and between the third and eleventh (our conversion from the precursor's numbering, positions 53–67 and 55–63).
| Property | Value | Source |
|---|---|---|
| Length | 21 amino acids | UniProt P05305; Yanagisawa 1988 |
| Sequence | CSCSSLMDKECVYFCHLDIIW | UniProt P05305, residues 53–73 |
| Formula | C109H159N25O32S5 | PubChem CID 16212950 |
| Molecular weight | 2,491.9 | PubChem CID 16212950 |
| Precursor | 212 residues, with a 17-residue signal piece | UniProt P05305 |
| Intermediate | Big endothelin-1, 38 residues | UniProt P05305 |
The five sulfur atoms in the formula match the sequence: four cysteines and one methionine (our count).
The three endothelins
A year after the discovery, a second paper showed that humans carry three separate endothelin genes (Inoue et al. 1989, PMID 2649896). Each predicts a 21-residue peptide: the original, now ET-1; ET-2, which differs at two positions; and ET-3, which differs at six. All three raised blood pressure when the synthetic peptides were injected into anaesthetised rats — an animal result.
How it is used in medicine: by being blocked
No one is given endothelin as a treatment. A search of FDA's drug database for endothelin as an active ingredient returned nothing on 2026-11-13; the same search for glucagon returned 12 applications, so the search itself works.
What is approved is a class of drugs that block endothelin's receptors. None is a peptide.
| Drug (brand) | First US approval | Approved for (label, shortened) |
|---|---|---|
| Bosentan (Tracleer) | 2001-11-20 | Pulmonary arterial hypertension |
| Ambrisentan (Letairis) | 2007-06-15 | Pulmonary arterial hypertension in adults |
| Macitentan (Opsumit) | 2013-10-18 | Pulmonary arterial hypertension in adults |
| Sparsentan (Filspari) | 2023-02-17 | IgA nephropathy; focal segmental glomerulosclerosis |
| Aprocitentan (Tryvio) | 2024-03-19 | Hypertension not adequately controlled on other drugs |
| Atrasentan (Vanrafia) | 2025-04-02 | Proteinuria in IgA nephropathy (accelerated approval) |
Dates are the original approvals in Drugs@FDA; indications are from each product's current label in openFDA, both read 2026-11-13. Sparsentan blocks an angiotensin receptor as well; the hormone behind that second target is described in the angiotensin entry.
Two trials show the size of effect behind the first indication. In the bosentan trial of 213 patients, the six-minute walking distance at week 16 was 44 metres better than placebo (95% confidence interval 21 to 67; PMID 11907289). In the macitentan trial of 742 patients, the combined endpoint of death or worsening disease occurred in 46.4% on placebo and 31.4% on the 10 mg dose (PMID 23984728). Both were read as abstracts.
What the labels warn about
Every one of the six labels carries a boxed warning on embryo-fetal toxicity — harm to an unborn child — and is contraindicated in pregnancy. The bosentan and sparsentan labels add a boxed warning on liver toxicity and are supplied only through a restricted programme. The aprocitentan label states that no controlled trial has shown it reduces heart attacks or strokes, and the atrasentan label states that it "has not been established" whether the drug slows the decline of kidney function.
Endothelin itself in human studies
ClinicalTrials.gov returned 58 studies with endothelin-1 named under interventions (2026-11-13). The first results this entry read are studies about endothelin — measuring it in blood, or probing its role in blood flow, as in a 16-person study at the optic nerve in healthy volunteers (NCT00915070) — and one is a trial of the blocker bosentan (NCT00226889). None is a trial of endothelin as a treatment. The 58 records were not all opened, so the count is a ceiling, not a tally of studies that gave the peptide to people.
What is not established
- Any benefit from taking endothelin. Nothing in the record suggests one, and its known action is to narrow vessels.
- Whether atrasentan slows kidney decline in IgA nephropathy; its own label says this awaits a confirmatory trial.
- Whether aprocitentan reduces cardiovascular events; its label says no controlled trial shows it.
Where it stands
- Endothelin as a product: none approved; none found in FDA's database.
- Blockers: six approved in the United States, 2001 to 2025.
- Research record: PubMed 16,708 title records (33,595 mentioning it in title or abstract), 1,097 tagged as randomised controlled trials; ClinicalTrials.gov 363 studies mentioning endothelin (2026-11-13).
Related reading
The body's vessel-narrowing signals have counterweights: the natriuretic peptides that relax vessels and shed salt, and bradykinin, a short peptide that widens them. Vasopressin, another vessel-constricting hormone, works through different receptors. The 1988 paper noted that parts of endothelin resemble a group of neurotoxins; a peptide toxin in this library is melittin from bee venom.
